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Background/aim: There is no study in the literature in which only chest computed tomography (CT) findings of deceased cases obtained
at admission were examined, and the relationship between these findings and mortality was evaluated.
Materials and methods: In this retrospective study, a total of 117 deceased patients with COVID-19 infection confirmed by positive
polymerase chain reaction and undergone chest CT were enrolled. We evaluated initial chest CT findings and their relationship, location,
prevalence, and the frequency with mortality.
Results: The mean age of patients was 73 ±18 years; 71 of all patients were male and 46 were female. The predominant feature was
pure ground-glass opacity (GGO) lesion (82.0%), and 59.8% of cases had pure consolidation. There was no cavitation or architectural
distorsion. Pericardial effusion was found in 9.4% the patients, and pleural effusions were found in 15.3% of them. Mediastinal
lymphadenopathy was only 11.9% in total.
Conclusion: In deceased patients, on admission CTs, pure consolidation, pleural and pericardial effusion, mediastinal LAP were more
common than ordinary cases. It was these findings that should also raise the concern when they were seen on chest CT; therefore, these
radiologic features have the potential to represent prognostic imaging markers in patients with COVID-19 pneumonia.
Key words: Chest computed tomography, COVID-19 infection, mortality

1. Introduction
The rapid spread of the COVID-19 associated pneumonia
and its urging mortality rate drew intense attention. The
number of Corona virus cases has exceeded two million
worldwide; as of September 10, 2020, the total number of
confirmed cases is 27,738,179 worldwide with a reported
mortality rate of 3.24% [1]. The first case was seen on
11 March 2020 in Turkey, the number of cases reached
28,455 as of 10 September 2020; 6895 patients (2.41 %)
died.
Although most patients have mild symptoms and
good prognosis, and sometimes disease progression
can be rapid, COVID-19 can develop severe illnesses
including pneumonia, pulmonary edema, acute severe
respiratory distress syndrome, multiple organ failure, or
it can even cause death [2,3]. Hence, accurate and early
recognition of the disease is crucial not only for prompt
implementation of treatment, but also for patient isolation
and effective public health surveillance, containment and
response [4]. Computed tomography (CT) is the major

diagnostic radiologic tool in identifying the COVID-19
associated pneumonia among the suspected cases [5]. In
our opinion, in addition to early diagnosis of the disease,
earlier identification of tomography findings of cases
with high risk of death can provide accurate information
about the patient’s prognosis before the general condition
of the patient deteriorates, thereby increasing the
probability of recovery of the patient with an effective and
timely treatment. This can only be achieved by evaluating
the radiological findings of the deceased cases and by
determining the findings that may be associated with
mortality.
However, to the best of our knowledge, there is no
study in the literature in which only chest CT findings
of deceased cases obtained at admission were examined,
and the relationship between these findings and mortality
was evaluated. Therefore, in this study, we investigated
the clinical and initial chest CT characteristics of 117
deceased COVID-19 cases obtained at admission and
examined the association with mortality.
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2. Materials and methods
2.1. Patients and groups
From March 15, 2020 to September 6, 2020, more than 8000
patients with suspected diagnosis of “viral pneumonia”
underwent chest CT scanning in our institution. In this
retrospective study, we included a total of 117 deceased
patients with confirmed COVID-19 infection, who were
hospitalized in Sakarya University Education and Research
Hospital, and who met the inclusion criteria.
1- Patients with two positive results on real-time
reverse transcriptase polymerase chain reaction (RTPCR) testing for SARS-CoV-2 on endotracheal aspirate,
nasopharyngeal swab, or oropharyngeal swab specimens.
2- Patients who underwent noncontrast-enhanced
thin-section chest CT scans upon hospital admission (in
first 12 h).
3- Age ≥ 18.
4- Chest CT scan showing any evidence of pneumonia.
5- Patients with symptoms compatible with COVID-19
and no more than 5 days from onset.
6- Patients who have not recovered and died despite all
kinds of treatment.
Currently, there is no specific treatment for COVID-19
with proven safety and effectiveness. According to the
guidelines recommendations in our country, 200 mg
Hydroxychloroquine tablet and/or 200 mg Favipiravir
tablet are used for 5 days in our hospital. In addition,
steroids and interleukin-6 blockers such as tosizumab are
used in cases with macrophage activation. In addition,
low molecular weight heparins were used in patients
with thromboembolism risk. In patients whose clinical
condition worsens despite medical treatment, intermittent
or continuous oxygen inhalation with positive pressure
in the presence of respiratory distress and intubation
treatment are used. If it is not sufficient, specific treatment
of accompanying organ failure is applied.
Clinical characteristics, laboratory findings, and
epidemiologic data together with chest imaging
manifestations of each confirmed cases were recorded.
All patients were clinically “moderate type”, and “in
early phase” in terms of chest CT process when they were
hospitalized.
Patients with a history of lung malignancy, lung
surgery, tuberculosis or atelectasis, patients without clinical
symptoms, patients in whom the date of the occurrence
of the first symptom was unknown and patients having
a normal chest CT scan, patients with severe artifacts on
CT images, patients who were younger than 18 years old,
and any of the other causes of pneumonia from common
bacterial and viral pathogens were excluded from the
study.
2.2. Chest CT scan
Chest CT imaging was performed on a Toshiba
Aquilion CFX 64-detector CT scanner (Toshiba Medical
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Systems, Osaka, Japan). CT images were acquired at full
inspiration with the patient in supine position and without
administration of intravenous contrast medium. The
scanning range was from the apex of lung to costophrenic
angle. CT scan parameters are as follows: 64 slice slice of
0.5 mm with each 350 ms revolution, 13 cm coverage in
patient axis direction, max scan range 180 cm, Gantry max
clearance 180 cm, 70 kW HF generator with 400 ms scan
speed.
2.3. Review of CT images
We evaluated 19 major imaging features described based on
Fleischner Society glossary of terms for thoracic imaging
in previous studies [6]: ground-glass opacities (GGO),
consolidation, crazy-paving pattern, air bronchogram,
interlobular or intralobular septal thickening, centrilobular
nodules, reverse halo/perilobular pattern, halo sign,
architectural distortion, cavitation, tree-in-bud, bronchial
wall thickening, reticulation, subpleural parenchymal
bands, plevral thickening, traction bronchiectasis,
intrathoracic lymph node enlargement (more than 1 cm in
short-axis diameter), vascular enlargement in the lesion,
pleural and/or pericardial effusions.
Two senior radiologists (Y.G and M.H.O with 15
years of experience in interpreting chest CT imaging,
respectively) evaluated the scanned images separately to
identify chest CT characteristics of each patient. The focus
was to observe whether lesions identified on the chest
CT images involved both lungs and several lung lobes. A
detailed analysis and evaluation of the imaging appearance
concerning each of the lesions identified included: (i)
the location and the number of lesions, (ii) the specific
distribution of the lung lobe, (iii) lesion type.
Locations referred to different lobes and segments
were involved. The distribution of the lesions was classified
as: 1. upper, middle or lower zones, 2. peripheral or
central 3. left, right or bilateral lungs. In this study, lung
lobe distribution information included the right upper
lobe (RUL), the right middle lobe (RML), the right lower
lobe (RLL), the left upper lobe (LUL), and the left lower
lobe (LLL). In addition, the distribution of the lung field
included the peripheral or central zone and whether the
peripheral and central zones were affected simultaneously
(diffuse). The peripheral lung was defined as the outer
one-third of the lung, and the central lung was defined as
the inner two-thirds of the lung. The number of segments
containing a specific category of opacities per patient were
counted.
The radiologist-defined lesion number and
percentages of the whole lung, RUL, RML, RLL, LUL LLL
were recorded, respectively. A computerized quantitative
approach was used to evaluate the severity of COVID-19
in the whole lung, right lung, left lung, upper lobes, lower
lobes, and each of the 5 lobes.
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The clinical parameters included age, sex, time from
illness onset to hospital admission, comorbidities (systemic
hypertension, diabetes mellitus, coronary heart disease,
chronic renal disease, and chronic obstructive pulmonary
disease), symptoms, clinical vital signs were collected and
evaluated.
The main symptoms of patients detected at the first
appication were fever, weakness, sore throat, dry cough,
dyspnea, sputum, chest pain, fatique and myalgia, nause/
vomiting, headache, respiratory rate (breathe/minute)
heart rate (beat/minute).
2.4. Statistical analysis
All statistical analyses were performed with SPSS software
version 21.0 (SPSS Inc., Chicago, IL, USA) and P-values
<0.05 were considered statistically significant. Continuous
variables were expressed as median and compared with
Student t-test or the Mann–Whitney U test); categorical
variables were expressed as percentage and compared by
χ2 test or Fisher’s exact test. In addition, the multivariate
logistic regression analysis was performed to identify the
relationship between mortality and initial CT features.
Receiver operator characteristic (ROC) curve analysis
was performed to calculate the threshold, specificity,
sensitivity, and accuracy for the determination of possible
factors (among clinical features and initial chest CT
findings) on mortality.
3. Results
3.1. Clinical characteristics
In the full cohort, the patients’ ages ranged from 28 to 95
years with a mean of 73 ± 18 years; 71 of all patients were
male and 46 were female.
The median length of hospital stay was 22±14 days,
and the time of symptom onset before CT (range 0–5 days)
was 3.9±1.6.
The prevalence of hypertension was 37.6 % (n: 44) while
chronic obstructive pulmonary disease, diabetes mellitus,
chronic renal disease, coronary heart disease, malignancy,
33.3 % (n: 39), 11.9% (n:14), 6.8% (n:8), 16.2% (n:19), and
7.6% (n:9), respectively.
The most common clinical symptoms were dyspnea
(97/117, 82.9%), fever (93/117, 79.4%), sputum (88/117,
75.2%), dry cough (87/117, 74.3%), and weakness (85/117,
72.6%). In addition, mean respiratory rate of patients
(breath/min) was 23 ± 10, and heart rate (beat/minute)
was 85 ± 16.
The demographic, clinical data and underlying disease,
the rates of clinical symptoms, and vital signs of 117 patients
at the time of admission has been shown in Table 1.
3.2. Chest CT findings
The predominant feature was pure GGO lesion (96/117,
82.0%), and 59.8% (70/117) of cases had pure consolidation.

Table 1. The demographic and clinical data and underlying
disease of 117 patients.
Characteristics

All (n:117)

Age (years)

73 ± 18 (28–95)

Sex (M/F)
Symptom onset before CT,
(range, 0–5 days)
The median length of hospital
stay (day)
Coexisting comorbidities

71/46

COPD

39 (33.3%)

Diabetes

14 (11.9%)

Hypertension

44 (37.6%)

Chronic renal disease

8 (6.8%)

Coronary heart disease

19 (16.2%)

Malignancy

9 (7.6%)

Clinical symptoms/Vital signs

(n,%)

Fever

93 (79.4%)

Weakness

85 (72.6%)

Sore throat

44 (37.6%)

Dry cough

87 (74.3%)

Dyspnea

97 (82.9%)

Sputum

88 (75.2%)

Chest pain

48 (41.0%)

Fatigue or myalgia

83 (71.0%)

Gastrointestinal symptoms

36 (30.7%)

Headache

22 (18.8%)

Respiratory rate (breath/min)

23 ± 10

Heart rate (beat/min)

86 ± 16

3.9 ± 1.6
22±14
(n,%)

Data reported as Mean ± SD or n (%) as appropriate.
Abbrevations: COPD: Chronic Obstructive Pulmonary Disease,
CT: Computerized Tomography.

In addition, 46 patients (39.3%) had mixed (GGO and
consolidation) lesion (Figure 1a, 1b), and 6 patients (5.8%)
had neither GGO nor consolidation.
There was no cavitation or architectural distorsion in
our cohort of cases. Halo sign (2/117, 1.7%), reverse halo
sign (3/117, 2.5%), vascular enlargement (3/117, 2.5%),
reticulations (4/117, 3.4%), and tree-in-bud nodularity
(4/117, 3.4%) were also rare findings. In addition, crazy
paving patern (5/117, 4.2%), centrilobular nodules (6/117,
5.1%), bronchial wall thickening (6/117, 5.1%), subpleural
bands (7/117, 5.9%), air-bronchograms (9/117, 7.7%),
and pleural thickenings (12/117, 10.2%) were other rare
findings that which were detected.
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Figure 1. The presence of GG0 (A) and GGO together with widespread consolidation (B) in the axial lung window section of admission
chest CT of these patients (1a: 64 years age, male, with hpertension; 1b: 43 years age, male) who lost their lives, draw attention.
Thick little arrows: ground glass opacity; thin big arrow: consolidation.

Pericardial effusion was found in 11/117 (9.4%) of
patients (Figure 2), and pleural effusions were found in
18/117 (15.3%) of patients (Figure 3), and the number of
patients with mediastinal lymphadenopathy was only 14
(11.9%) in total (Figure 4).
The number of lung lesions on chest CT scans were
counted for each infected patient and comprised a total of
1100 lesions, and CT score (number of lesion per patient)
was 9.40.
A computerized quantitative approach was used to
evaluate the prevalence of Chest CT lesions of COVID-19
infection, in the whole lung, right lung, left lung, and each
of the 5 lobes. Of a total of 1100 lesions spread the whole
the lung, 176 lesions (10.6%) were located in the RUL,
59 (5.3%) were in RML, 260 (23.6%) were in RLL, 237
(21.5%) were in LUL, 368 (33.4%) were in LLL. While the
lobe with the least lesion involvement was RML, the lesion
was mostly detected in LLL.
The chest CT features, including the location, extent
and distribution of lesions were summarized in Table 2.
When the effect of age on lesion distribution was
evaluated by dividing the patients into two groups as those
over 65 years old (n:69) and those aged 65 and under
(n:48), only pure consolidation (48 patients, 55.0% vs
22 patients, 45.8%, P: 0.004) and the number of patients
with pleural effusion (14 patients, 20.2% vs 4 patients,
8.3%, P: 0.011) were statistically different, and these two
tomography findings were significantly more pronounced

932

Figure 2. Significant pleural effusion was detected in the Chest
CT of this patient (70 years age, male, with diabetes mellitus),
and it was shown that the presence of pleural effusion was an
important determinant of mortality in our patients over 65 years
of age.
White arrows: pleural effusion.

in patients over 65 years of age. There was no significant
difference in other findings (P > 0.05).
Comparison of chest CT findings of the patient group
>65 years of age and the group ≤ 65 years of age was shown
in Table 3.
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mortality was examined, and, in this analysis, advanced
age (> 65 years), pleural effusion, and the presence of
consolidation were found to be statistically significant
factors associated with mortality. The results of multivariate
logistic regression analyzes were shown in Table 4.
In addition, for ROC analysis, the area under the ROC
curve (AUC) of pleural effusion was 0.92 (95% CI:0.830.97; P<0.001) for the prediction of poor prognosis and
mortality. When the cutoff value of age was 65 years,
the sensitivity and specificity were 93.7% and 85.9%,
respectively. In addition, AUC was found 0.80 (95%
CI:0.71–090; P : 0.022) for consolidation and the sensitivity
and specificity were 77.7% and 69.5%, respectively.

Figure 3. At the admission chest CTs of this case (58 years age,
male, with hypertension and coronary artery disease), there was
pericardial effusion in coronal section. This case also died despite
all kinds of treatment.
White arrows: pericardial effusion.

Figure 4. In the chest CT of the patient (64 years age, female, with
diabetes mellitus and chronic renal disease), it was seen that there
was marked right lower paratracheal (4R) lymphadenopathy in
the noncontrast axial section.
White arrow: lymphadenopathy.

In our cases, advanced age (especially over 65 years),
high CT score, presence of consolidation, pleural effusion,
pericardial effusion, and mediastinal lymphadenopathy
were noted to be higher than usual. With multivariate
logistic regression analysis, the relationship of each with

4. Discussion
The number and prevalence of tomography lesions
that occur from the onset of symptoms in COVID-19
pneumonia increase and/or change day by day and at every
stage, depending on the positive or negative course of the
disease [7]. Therefore, there are group differences of some
CT signs among different CT stages, though GGOs and
consolidation were most frequently seen in each CT stages
without group differences in patients with COVID-19
pneumonia [8]. However, in our study, chest tomographies
of all cases were taken within the first 5 days when their
symptoms started (in the early stage as a CT stage, in the
moderate stage as a clinical stage), and were not taken
again later or were not evaluated even if they were taken.
In our cases, the predominant abnormal chest CT
patterns observed were bilateral, multilobar, diffuse
(central plus peripheral), and infiltrated the lower lobes
GGOs; however, consolidations, pericardial and pleural
effusion, mediastinal lymphadenopathy occured more
often than avarage of usual cases [9]. In the literature, from
the ordinary stage to the severe/critical stage, in more
cases, the number of involved lung segments and lobes,
the frequencies of consolidation, intra/interlobular septal
thickening, crazy-paving pattern, and air bronchogram
all increased [10]. However, in our study, unlike the
critical case features mentioned previously, crazy-paving
pattern and air bronchogram were much less common,
and extrapulmonary findings of pleural and pericardial
effusion and lymphadenopathy (which have been shown to
be poor prognostic indicators in cases of viral pneumonia)
were seen more frequently on initial tomography [11].
Pan et al. classified CT findings of COVID-19
according to 4 temporal stages as early, rapid progressive,
peak (consolidation), and absorption (dissipation) stages
[7]. Our cases were symptomatic and since chest CTs were
taken within the first 5 days after the onset of symptoms,
they were expected to show radiological findings of early
stage or early period of rapid progressive stage. Each CT
stage has its characteristic CT signs and performances,

933

GÜNDÜZ et al. / Turk J Med Sci
Table 2. The chest CT findings of 117 patients at the time of admission.
Chest CT findings

All (n:117)

Chest CT findings

All (n:117)

Ground glass opacities (GGO)

96 (82.0%)

Vascular enlargement

3 (2.5%)

Consolidation

70 (59.8%)

Architectural distortion

0 (0%)

Mixed (GGO and consolidation)

46 (39.3%)

Tree-in-bud nodularity

4 (3.4%)

Neither GGO nor consolidation

6 (5.8%)

Bronchial wall thickening

6 (5.1%)

Halo sign

2 (1.7%)

Crazy paving pattern

5 (4.2%)

Reverse halo/perilobular pattern

3 (2.5%)

Pleural effusion

18 (15.3%)

Centrilobular nodules

6 (5.1%)

Pericardial effusion

11 (9.4%)

Plevral thickening

12 (10.2%)

Mediastinal lymphadenopathy

14 (11.9%)

Reticulation

4 (3.4%)

Septal thickening interlobuler

16 (13.6%)

Air bronchograms

9 (7.7%)

Septal thickening intralobuler

15 (12.8%)

Subpleural bands

7 (5.9%)

Bronchiectasis

22 (18.8%)

Cavitation

0 (0%)

Emphysema

17 (14.5%)

Transverse distribution

(n/%)

Unilateral involvement

7 (6.0%)

Central

6 (5.2%)

Bilateral involvement

110 (94.0%)

Peripheral

53 (45.3%)

Total number of lesions

1100

Diffuse (central+peripheral)

58 (49.5%)

Lobar location

Lesion number

Right upper lobe (RUL)

176

CT score (lesion number/n)
9.40
Symptom onset before CT, (range, 0–5
3.9 ± 1.6
days)
1 lobe involvement (n/%)
8 (6.8%)

Right middle lobe (RML)

59

2 lobe involvement (n/%)

14 (12%)

Right lower lobe (RLL)

260

3 lobe involvement (n/%)

20 (17%)

Left upper lobe (LUL)

237

4 lobe involvement (n/%)

34 (29%)

Left lower lobe (LLL)

368

5 lobe involvement (n/%)

41 (35%)

making it possible for radiologists and physicians to quickly
determine the stage of the pneumonia [12]. However, what
is important is to determine the clinical and radiological
findings that may be associated with high mortality before
the patient’s general condition deteriorates and reaches the
critical stage, for predicting the prognosis and outcome,
taking necessary preventive measures, especially in highrisk cases, and ensuring early treatment of the patient, thus
preventing or reducing mortality.
As a matter of fact, in the early stage (days 1–4 of
symptomatic presentation), chest CT findings include
single or multiple GGOs distributed subpleurally in
the lower lobes unilaterally or bilaterally, or GGO
combined with interlobular septal thickening, patchy
consolidations in ordinary cases. In addition, interlobular
septal thickening, air bronchus sign, intralesional and/
or perilesional bronchiectasis, and bronchial wall
thickening were less seen than in the progressive stage.
The reticular sign, pleural thickening, and interlobar
fissure displacement were not common, and the frequency
of pleural effusion, pericardial effusion, and mediastinal
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lymphadenopathy was relatively small in early stage. In
the rapid progressive stage (days 5–7 of symptomatic
presentation), the infection exacerbates rapidly and
expands with a bilateral multilobe distribution and diffuse
GGO, crazy paving pattern, air bronchograms and large,
light consolidative opacities are formed [7,12–14].
In a study, patients with mild form of disease showed
pure GGO more often than patients with severe disease;
on the contrary, pure consolidation was more common in
patients with severe disease. Thus, it could be speculated
that pure GGO might be associated with early or mild
stage of disease; on the contrary, pure consolidation
might show severe clinical form or be seen at a more
advanced stage [13-16]. In another study, on admission,
GGO, consolidation were the major CT fndings in both
groups, bilateral lung involvement, difuse distribution
were more common in nonsurvivors than survivors [16].
Considering the presence of consolidation together with
GGO, which was seen as an early finding in our cases,
although GGO was seen in usual rate as a typical finding,
consolidation was more common than avarage of usual
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Table 3. Comparison of chest CT findings of the patient group >65 years of age and the group ≤ 65 years of age.
Age ≤ 65 (28–65)

Age > 65 (66–95)

Ground glass opacities (GGO)

(n: 48)
39 (81.2%)

(n: 69)
57 (82.6%)

Consolidation

22 (45.8%)

48 (69.5%)

0.004

Mixed (GGO and consolidation)

20 (41.6%)

26 (37.6%)

0.320

Neither GGO nor consolidation

2 (4.1%)

4 (5.7%)

0.632

Halo sign

0 (0%)

2 (2,8%)

0.199

Reverse halo/perilobular pattern

1 (2.0%)

2 (2.8%)

0.704

Centrilobular nodules

3 (6.2%)

3 (4.3%)

0.298

Plevral thickening

5 (10.4%)

7 (10.1%)

0.933

Reticulation

2 (4.1%)

2 (2.8%)

0.714

Air bronchograms

4 (8.3%)

5 (7.2%)

0.612

Subpleural bands

2 (4.1%)

5 (7.2%)

0.084

Cavitation

0 (0%)

0 (0%)

------

Vascular enlargement

1 (2.0%)

2 (2.9%)

0.771

Architectural distortion

0 (0%)

0 (0%)

------

Tree-in-Bud nodularity

2 (4.1%)

2 (2,8%)

0.489

Bronchial wall thickening

3 (6.2%)

3 (4.3%)

0.117

Pleural effusion

4 (8.3%)

14 (20.2%)

0.011

Pericardial effusion

4 (8.3%)

7 (10.1%)

0.232

Mediastinal lymphadenopathy

5 (10.4%)

9 (13.0%)

0.318

Crazy paving pattern
Septal thickening interlobuler
Septal thickening intralobuler
Bronchiectasis

3 (6.2%)
7 (14.5%)
6 (12.5%)
8 (16.6%)

2 (2.9%)
9 (13.0%)
9 (13.0%)
14 (20.2%)

0.059
0.711
0.815
0.664

Emphysema

7 (% 14.58)

10 (14.49%)

0.992

Total number of lesions

522

578

0.196

9.28

0.750

4.0±1.7

0.213

24±16

0.717

Chest CT findings

CT score (lesion number/n)
9.52
Symptom onset before CT, (range, 0–5
3.8±1.4
days)
The median length of hospital stay (day) 20±13

Table 4. Multivariable logistic regression analysis for predicting
of the mortality in 117 patients hospitalized with COVID-19.
Characteristics

Odds ratio

95% CI

P value

Age (> 65 years) 3.53

1.17–6.11

0.01

Pleural effusion 4.94

1.01–10.82

<0.001

Consolidation

1.09–1.68

0.03

1.33

[8]. It was noteworthy that there were ≥3 lobes involved
in 4/5 of the cases, and 4-5 lobes were involved in 2/3 of
the cases.

P value
0.781

The rate of patients with interlobular septal thickening
and air bronchogram was higher in patients with severe
disease than in patients with mild disease, indicating that
these two findings could relate to advanced or late stage
of COVID-19 pneumonia or coexistence of superimposed
processes, such as pulmonary edema [10,18]. In addition,
it was stated that severe and widespread involvement
increases the frequency of architectural distortion, and
bronchiectasis is seen more frequently as a concomitant
disease [18,19]. Likewise, in our study, it was found
that both bronchiectasis and emphysema were coomon
underlying disease. However, in contrast, the fact that
air bronchogram and arcitectural distortion were not
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encountered frequently in our study suggests that these
findings were not seen in the early period, that is, they
may not be seen in the tomographies taken within the first
5 days. Wang et al. investigated changes of CT findings
in COVID-19 patients, and they found that the extent of
pulmonary involvement peaked during days 6–11 after the
onset of initial symptoms [20].
It is common to see the crazy paving pattern in
chest CTs taken 8–9 days after the onset of symptoms.
However, increasing alveolar edema, exudate lymphocyte
infiltrations, accumulation in the interstitial space,
radiologically, the formation of crazy paving pattern,
and the increase in the frequency of this appearance
indicate the progress of the disease, and a poor prognosis
[21–23]. In our cases, since the tomographies were taken
within the first 5 days of the onset of symptoms, the
pathophysiological process that would lead to an increase
in the frequency of the crazy paving pattern has not yet
settled, so this finding indicating a poor prognosis is not
common in the first 5 days. Similar evaluation can be made
for the development of air bronchogram, and the increase
in air bronchogram frequency is again a sign of severe/
advanced disease and shows poor prognosis [22], but this
finding is not a common finding in CTs taken within the
first 5 days in patients who died.
Besides this, it has been showed that severe/
critical patients have higher incidences of lymph node
enlargement, pericardial effusion, and pleural effusion than
ordinary patients [9,11]. Lymphadenopathy was usually
rare in mild form of viral pneumonias, it was reported
in 4%–8% of patients with COVID-19 [22]. Moreover,
lymphadenopathy was considered one of the significant
risk factors of severe/critical COVID-19 pneumonia
[14]. Pleural and pericardial effusion were uncommon,
manifesting mainly in patients with severe disease, which
may indicate parapneumonic effusion or fluid overload
[24]. We found more mediastinal lymphadenopathy
(11.9%), pleural (15.3%) and pericardial effusion (9.4%)
than usual, on the admission CT of our deceased patients
[9], and we found that pleural effusion was a strong
predictor of mortality, especially in patients over 65 years
of age. These extrapulmonary lesions might indicate the
occurrence of severe inflammation. In the presence of
these findings, it is suggested that the cases carry a high
risk for mortality and that we must take precautions as
soon as possible.
In a study, older patients (>60 years) tended to have
more areas of lung involvement with more lobes affected
and more pleural thickening [25]. In another study,
patients older than 50 years had more extensive disease
with more consolidation as compared to patients younger
than 50 years old. They tended to have more architectural
distortion, bronchiectasis, mediastinal and hilar
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lymphadenopathy, pleural effusions, and worse outcomes
than younger patients [9].
In accordance with the previous studies, in a different
study, old patients (63–78 years) with more comorbidities
such as hypertension, diabetes, and coronary heart disease
were more inclined to develop fatal ARDS in nonsurvivor
group [26]. Our patient sample was different from those
in other studies as we evaluated the clinical and imaging
features in the deceased cases with COVID-19. Since
emphysema and bronchiectasis (14.5% and 18.8%) as
underlying dieases were common in the deceased patients,
it could be hypothesized that an underlying lung disease
might also cause worse clinical outcome. Furthermore,
patients with hypertension (37.6%), and the old patients
(73±18) appeared more frequently in the deceased cases.
These findings suggested that 2019-nCoV was more likely
to infect elderly people with chronic comorbidities as a
result of the weaker immune functions of these patients, and
2019-nCoV-associated death was also related to elder age
and underlying illnesses, especially hypertension, cardiac,
and pulmonary disease.
In a previous study, patients in deceased group were
much older than survivors, and logistic regression analysis
revealed that age ≥ 65 years is a strong predictor for death
of COVID-19 pneumonia. Actually, in the whole cohort
of 179 COVID-19 pneumonia patients, no one died who
was younger than 50 years, whereas 17 (81%) of deceased
patients were older than 65 years [27]. However, in our
study, there were 48 cases under the age of 65, 11 cases
under the age of 50, and the youngest patient who died was
28 years old. As such, the number of cases in our study was
considerably higher than the case number of this study, and
includes younger patients. As a matter of fact, although
many findings were similar in number and characteristics
in cases under 65 years of age compared to cases above 65
years of age, halo sign, subpleural band, pericardial effusion,
mediastinal LAP and brochiectasis tended to be more,
whereas the number of cases with pleural effusion (4 vs 14,
P: 0.011) and pure consolidation number (45.8% vs 69.5%,
P: 0.004) were statistically significantly higher. In the ROC
analysis, it was seen that pleural effusion had high sensitivity
and specificity as a mortality predictor in cases above 65
years of age, especially when the age of 65 was cutoff, and the
detection of pleural effusion and pure consolidation in chest
CT on hospital admission drew attention as a high mortality
predictor, especially in patients over 65 years of age.
In deceased patients, on admission CT, extensive,
bilateral, multilobar, basal, both central and peripheral
GGO and consolidative opacities, without cavitation and
architectural distortion were occured. In addition, rarely air
bronchogram, pleural and bronchial wall thickening, crazy
paving pattern, subpleural bands, centrilobular nodules,
pure consolidation, pleural and pericardial effusion,
mediastinal LAP, and emphysema and very rarely halo
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sign, reverse halo sign, reticulation, vascular enlargement,
were detected. It was these findings that should also raise
the concern when they were seen on chest CT; therefore,
these radiologic features have the potential to represent
prognostic imaging markers in patients with COVID-19
pneumonia. In the previous studies, the radiological
findings of the patients who died were compared with
those who survived, and comments were made based on
the findings obtained [16,17]. However, in our study, only
the CT findings of the deceased cases taken at the time of
admission were evaluated retrospectively, and only these
CT findings were interpreted without causing confusion.
Therefore, there are not many similar studies in the
literature or its methodology is quite different from studies
considered to be similar.
There are a few limitations to our study. First, the sample
size was relatively small owing to the strict selection criteria
applied to these patients, only 117 patients with confirmed
COVID-19 were included. Although it is probably one of
the studies with the highest number of patients in which
only deceased patients were recruited, it is not definitive,
studies containing more cases are needed to prevent death
with the patient, but we underline that this is not desired.
A more comprehensive approach could be provided to
make the good or poor prognosis predictable from the
initial chest CT findings. However, the desire and effort of
publishing the valuable radiological findings obtained in a
pandemic as soon as possible to be beneficial to the public
health can be defined as another underlying factor of this
limitation.
Second, we focused on baseline CT findings that
clinicians and radiologists first encountered, rather than

findings from follow-up CT scans. Thus, we did not apply
control CT to our patients and did not evaluate what was
done. In order to evaluate changes in lung parenchyma that
may develop over time during the course of the disease,
taking and evaluating lung CT for control or follow-up
in patients was out of the protocol of our study and we
did not apply this method for many studies. In the future,
studies with larger patient groups and longer follow-up
may be performed to evaluate the prognostic value of the
first CT features.
Third, in our study, we did not evaluate the role of chest
CT in monitoring response to treatment.
Fourth, no autopsy was performed in the deceased
patient group. Upon comparison with the pathological
results, additional and a more precise interpretation of the
CT image signs will be available in the future work.
Lastly, this was a retrospective study with initial CT
images during hospitalization, mainly demonstrated the
early phase of chest CT lesions in patients with COVID-19.
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